18 results about "Lipoma" patented technology

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

Doxycycline injections improve the appearance of cosmetically significant lower eyelid festoons and malar edema, as well as of the jowls. The doxycycline is also useful for reducing edema of turbinates, the nasal concha or conchae shell-shaped networks of bones, vessels, and tissue within the nasal passageways that are responsible for warming, humidifying, and filtering the air as it is inhaled. The doxycline, in a concentration preferably of greater than 10 to 20 mg / ml, preferably in combination with a local anesthetic and optionally with a vasoconstrictor such as epinephrine and a pH buffering agent, is injected into the subcuticular space at the site of swelling. The high viscosity limits the spread of the doxycycline to the area to be treated. The resulting sclerosis prevents fluid accumulation. The doxycline also decreases swelling due to fat, by causing a decrease in lipomas.

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal / Skeletal Anomalies and / or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

Provided herein are compositions and methods for the treatment of Multiple Symmetric Lipomatosis (MSL) and related diseases and conditions. In particular, the present disclosure provides methods for the use of leptin receptor agonists (e.g., synthetic (e.g., recombinant) leptin, e.g., Metreleptin), in the treatment of Multiple Symmetric Lipomatosis (MSL) and related diseases and conditions.

Doxycycline injections improve the appearance of cosmetically significant lower eyelid festoons and malar edema, as well as of the jowls. The doxycycline is also useful for reducing edema of turbinates, the nasal concha or conchae shell-shaped networks of bones, vessels, and tissue within the nasal passageways that are responsible for warming, humidifying, and filtering the air as it is inhaled. The doxycline, in a concentration preferably of greater than 10 to 20 mg / ml, preferably in combination with a local anesthetic and optionally with a vasoconstrictor such as epinephrine and a pH buffering agent, is injected into the subcuticular space at the site of swelling. The high viscosity limits the spread of the doxycycline to the area to be treated. The resulting sclerosis prevents fluid accumulation. The doxycline also decreases swelling due to fat, by causing a decrease in lipomas.

The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor / —inactivator and α-lipoic acid and / or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and α-lipoic acid and / or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease.

The invention relates to application of 18F-FAPI-42 in preparation of a product for diagnosing lung lymphangioleiomyomatosis, and belongs to the technical field of radiography imaging agents. The invention discloses an application of < 18 > F-FAPI-42 in preparation of a product for diagnosing lung lymphangioleiomyomatosis. FAPI is a novel PET tracer agent, PET / CT of FAPI has the advantages of being low in radiation exposure, fast in-vivo metabolism and free of influences of blood glucose level changes, and patient tolerance is better. Compared with 68Ga, the radioactive isotope 18F has a longer half-life period and higher electron energy, and has more advantages in clinical use. As a novel PET / CT tracer, the 18F-FAPI-42 is remarkably superior to a traditional tracer 18F-FDG in the aspects of evaluating the condition of an LAM patient and identifying the focus of the LAM patient, including renal vascular smooth muscle lipoma, mediastinal lymphatic vessel myoma, abdominal lymphatic vessel myoma and pelvic lymphatic vessel myoma.

The present invention discloses a magnetic resonance fingerprinting imaging method with variable number of echoes, in addition to conventional MRF coding such as changing the excitation pulse angle, the method also introduces the change of the number of echoes, so that quantitative maps of B0, B1+, T1 and T2* can be obtained in a single scan. Further, if the echo time corresponding to the in-phase, opposed-phase and in-phase of water and fat is set for three consecutive echoes, the present invention can also image water and fat, and achieve the accurate quantification of B0, B1+, T1w, T1F, [T2*]w and [T2*]F. Through in vivo experiments and simulations, the effectiveness of the present invention has been proved. Therefore, the present invention can provide multiple information representations for common brain diseases (glioma) and fatty diseases (such as lipoma, fatty liver, etc.), which is conducive to clinical diagnosis and treatment.

The utility model provides minimally invasive suction equipment for giant lipoma, which is characterized in that the front end of a negative pressure driving cavity is connected with a liposuction tube, the side wall of the negative pressure driving cavity is provided with a negative pressure interface, and the negative pressure interface is used for being connected with an air suction device so as to generate negative pressure in the negative pressure driving cavity; the driving rod is located in the negative pressure driving cavity, the cutter rod is located in the liposuction tube, the front end of the driving rod is connected with the cutter rod, and the rear end of the driving rod is driven by the driving motor to rotate; a spiral blade is arranged at the front end of the cutter bar, and a liposuction opening is formed in the side wall of the liposuction tube corresponding to a rotating area of the spiral blade. According to the minimally invasive suction equipment provided by the utility model, fat can be sucked through the fat suction port, the fat entering the fat suction port is crushed by the spiral blade under the rotation action of the cutter bar driven by the driving motor, and then the fat can be adsorbed and discharged to the rear end by the negative pressure driving cavity under the negative pressure action of the negative pressure interface; therefore, the fat is prevented from blocking the liposuction tube, and the refinement efficiency can be greatly improved.

Provided herein are compositions and methods using a therapeutic agent targeting mTORCI and a therapeutic agent targeting MDK for treating a Tuberous Sclerosis Complex (TSC)-associated disease, e.g., Angiomyolipoma (AML) and lymphangioleiomyomatosis (LAM), or for treating sporadic LAM / AML. Also provided are methods of identifying subjects for treatment, e.g., with checkpoint inhibitors.

This invention relates to the field of computer-aided diagnostic technology, and provides a method for constructing an intelligent pathological auxiliary diagnostic model for lipomas based on weakly supervised learning. The method includes acquiring several whole-slice images of lipomas; preprocessing the whole-slice images; constructing a structured square image patch dataset suitable for weakly supervised learning; classifying and storing the images according to their dataset and pathological label categories in a structured text index file; constructing a lightweight ViT model as the core network architecture, serializing and embedding the square image patches, learning features through a multi-layer self-attention mechanism, and connecting them to a global pooling classification head to form a weakly supervised diagnostic model that relies on image-level labels for end-to-end training; and applying weakly supervised training strategies and optimizations to the weakly supervised diagnostic model to achieve an interpretable intelligent diagnostic system for lipomas. This invention constructs an end-to-end solution suitable for weakly supervised learning of pathological images.

The invention provides application of AS-605240 in treatment of renal vascular smooth muscle lipoma related to nodular sclerosis, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, the AS-605240 can be used for directly inhibiting the cell growth of the renal vascular smooth muscle lipoma related to the nodular sclerosis, and the AS-605240 can be used for preparing a medicine for resisting the renal vascular smooth muscle lipoma related to the nodular sclerosis, so that a new potential medicine is provided for treating the renal vascular smooth muscle lipoma related to the nodular sclerosis. The invention proves that AS-605240 can promote apoptosis of renal vascular smooth muscle lipoma cells related to the nodular sclerosis through a non-mTOR target point PI3K / AKT, so that the AS-605240 can treat the renal vascular smooth muscle lipoma related to the nodular sclerosis, and has good treatment and improvement effects on the renal vascular smooth muscle lipoma related to the nodular sclerosis.

The utility model relates to a micro spoon knife for lipoma, which comprises a curette spoon and a cutting knife, the curette spoon and the cutting knife are respectively arranged at two ends of a connecting handle, the end part of the curette spoon is provided with a thin-wall spoon body with a concave middle part, and the end part of the cutting knife is provided with a blade; the curette body is in an oval shape with the middle concave downwards, the oval shape is smoothly concave downwards from the edge to the middle, the curette spoon, the cutting knife and the connecting handle are of an integrated structure or a split structure, and the curette spoon and the cutting knife are both made of medical metal materials. The curette spoon and the cutting knife are manufactured into a whole, using is convenient, the end cutting edge facilitates small incision mode cutting, the other end adopts the design of the spoon for curetting adipose tissue, damage to a patient is small, the curette is suitable for minimally invasive surgery, operation of a doctor is easy, an open surgery is changed into the minimally invasive surgery, the clinical patient treatment cost is reduced, and the operation efficiency is improved. The disposable sterile medical instrument product is convenient for doctors to take and use, and meanwhile, the risk of cross infection of patients can be avoided.

The present invention belongs to the field of biomedicine technology and specifically relates to the use of artemisinin compounds in the preparation of drugs for treating tuberous sclerosis complex-associated renal angiomyolipoma. The artemisinin compounds can inhibit the growth of tuberous sclerosis complex-associated renal angiomyolipoma cells and have therapeutic efficacy in treating tuberous sclerosis complex-associated renal angiomyolipoma. Furthermore, artemisinin compounds are relatively abundant in source and relatively low in cost. Artemisinin compounds can be used to prepare drugs for treating tuberous sclerosis complex-associated renal angiomyolipoma, providing a new potential drug for the treatment of tuberous sclerosis complex-associated renal angiomyolipoma.

The invention belongs to the technical field of biological medicines, and particularly relates to application of cinobufotalin in preparation of a medicine for resisting renal vascular smooth muscle lipoma related to nodular sclerosis. The cinobufotalin can be used for directly inhibiting the growth of renal vascular smooth muscle lipoma cells related to the nodular sclerosis and improving the protein expression level of an apoptosis marker of the renal vascular smooth muscle lipoma cells related to the nodular sclerosis, and the cinobufotalin can be used for preparing the medicine for resisting the renal vascular smooth muscle lipoma cells related to the nodular sclerosis. Meanwhile, cinobufotalin is low in cost, and a novel, effective and low-cost potential medicine is provided for treatment of renal vascular smooth muscle lipoma related to nodular sclerosis.

The present invention provides a method for raising a poultry, comprising administering to the poultry a thiamine or a derivative thereof in an amount effective for reducing incidence or severity of an event in the poultry, improving meat quality of the poultry, or supporting muscle health or healthy muscle growth in the poultry. The event may be selected from the group consisting of wooden breast (WB), white striping (WS), myopathic lesions, vacuolations, lipogranuloma formation, myofiber splitting, fibrosis, necrosis, and a combination thereof. Also provided are a composition for raising a poultry and a method for preparing the composition as well as a package comprising a thiamine or a derivative thereof and instructions for raising a poultry.

The invention belongs to the technical field of biological medicines, and particularly relates to application of artemisinin compounds in preparation of medicines for resisting renal vascular smooth muscle lipoma related to nodular sclerosis. The artemisinin compound can inhibit the growth of renal vascular smooth muscle lipoma cells related to nodular sclerosis, has the efficacy of treating renal vascular smooth muscle lipoma related to nodular sclerosis, and meanwhile, the artemisinin compound is relatively rich in source, relatively low in cost and suitable for industrial production. The artemisinin compound can be used for preparing the medicine for treating the renal vascular smooth muscle lipoma related to the nodular sclerosis, and a new potential medicine is provided for treating the renal vascular smooth muscle lipoma related to the nodular sclerosis.